We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.
- Authors
Blanke, Charles D; Rankin, Cathryn; Demetri, George D; Ryan, Christopher W; von Mehren, Margaret; Benjamin, Robert S; Raymond, A Kevin; Bramwell, Vivien H C; Baker, Laurence H; Maki, Robert G; Tanaka, Michael; Hecht, J Randolph; Heinrich, Michael C; Fletcher, Christopher D M; Crowley, John J; Borden, Ernest C
- Abstract
To assess potential differences in progression-free or overall survival when imatinib mesylate is administered to patients with incurable gastrointestinal stromal tumors (GIST) at a standard dose (400 mg daily) versus a high dose (400 mg twice daily).
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Vol 26, Issue 4, p626
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2007.13.4452